Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.05.112 on February 28 2005

Journal of Clinical Oncology, Vol 23, No 16 (June 1), 2005: pp. 3697-3705
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kabbinavar, F. F.
Right arrow Articles by Novotny, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kabbinavar, F. F.
Right arrow Articles by Novotny, W. F.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

Fairooz F. Kabbinavar, Joseph Schulz, Michael McCleod, Taral Patel, John T. Hamm, J. Randolph Hecht, Robert Mass, Brent Perrou, Betty Nelson, William F. Novotny

From the University of California, Los Angeles (UCLA) School of Medicine, Los Angeles; Genentech Inc, South San Francisco, CA; Virginia Oncology Associates, Newport News, VA; Florida Cancer Specialists, Ft Myers, FL; Mid Ohio Oncology Hematology Inc, Westerville, OH; Louisville Oncology, Louisville, KY

Address reprint requests to Fairooz F. Kabbinavar, MD, Division of Hematology/Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095-7187; e-mail: fkabbina{at}mednet.ucla.edu

PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan.

PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age ≥ 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin ≤ 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed.

RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation.

CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.

Supported by Genentech Inc.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Bevacizumab Plus Fluorouracil: The Value of Being Part of a Developing Story
    Alberto Sobrero and Paolo Bruzzi
    JCO 2005 23: 3660-3662 [Full Text]


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Welch, K. Spithoff, R. B. Rumble, J. Maroun, and the Gastrointestinal Cancer Disease Site Group
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Ann. Onc., November 25, 2009; (2009) mdp533v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero and T. Macarulla
Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development
J. Clin. Oncol., November 20, 2009; 27(33): 5487 - 5491.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. DiBartolomeo, M.-A. Mazier, J.-L. Canon, V. Georgoulias, M. Peeters, et al.
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
Ann. Onc., November 1, 2009; 20(11): 1842 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Montagnani, C. Migali, and G. Fiorentini
Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
J. Clin. Oncol., October 1, 2009; 27(28): e132 - e133.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. T. Okita, Y. Yamada, D. Takahari, Y. Hirashima, J. Matsubara, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, H. Taniguchi, et al.
Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 595 - 600.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Kozloff, M. U. Yood, J. Berlin, P. J. Flynn, F. F. Kabbinavar, D. M. Purdie, M. A. Ashby, W. Dong, M. M. Sugrue, A. Grothey, et al.
Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
Oncologist, September 1, 2009; 14(9): 862 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
K E Schmid-Kubista, I Krebs, B Gruenberger, F Zeiler, J Schueller, and S Binder
Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study
Br J Ophthalmol, July 1, 2009; 93(7): 914 - 919.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, C. H. Kohne, H. K. Sanoff, B. M. Bot, M. T. Seymour, A. de Gramont, R. Porschen, L. B. Saltz, P. Rougier, C. Tournigand, et al.
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., April 20, 2009; 27(12): 1948 - 1955.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. M Gressett and S. R Shah
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Ann. Pharmacother., March 1, 2009; 43(3): 490 - 501.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, et al.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Clin. Oncol., February 10, 2009; 27(5): 672 - 680.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen
Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
J. Clin. Oncol., January 10, 2009; 27(2): 199 - 205.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey, M. M. Sugrue, D. M. Purdie, W. Dong, D. Sargent, E. Hedrick, and M. Kozloff
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
J. Clin. Oncol., November 20, 2008; 26(33): 5326 - 5334.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
JAMA, November 19, 2008; 300(19): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Meulenbeld, L. N. van Steenbergen, M. L. G. Janssen-Heijnen, V. E. P. P. Lemmens, and G. J. Creemers
Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004
Ann. Onc., September 1, 2008; 19(9): 1600 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. F. Kabbinavar, J. F. Wallace, E. Holmgren, J. Yi, D. Cella, K. J. Yost, and H. I. Hurwitz
Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Oncologist, September 1, 2008; 13(9): 1021 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol, August 1, 2008; 10(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Shitara, M. Munakata, O. Muto, and Y. Sakata
Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report
Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 493 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. R. Hecht
Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S15 - S21.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.-S. Yang, F. Rivera, et al.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
J. Clin. Oncol., April 20, 2008; 26(12): 2013 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, and T. Gruenberger
Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1830 - 1835.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Brostjan, K. Gebhardt, B. Gruenberger, V. Steinrueck, H. Zommer, H. Freudenthaler, S. Roka, and T. Gruenberger
Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels
Clin. Cancer Res., April 1, 2008; 14(7): 2065 - 2074.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier
Chemotherapy in Elderly Patients with Colorectal Cancer
Oncologist, April 1, 2008; 13(4): 390 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. D. Badgwell, E. R. Camp, B. Feig, R. A. Wolff, C. Eng, L. M. Ellis, and J. N. Cormier
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Ann. Onc., March 1, 2008; 19(3): 577 - 582.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Mathew, P. F. Thall, C. D. Bucana, W. K. Oh, M. J. Morris, D. M. Jones, M. M. Johnson, S. Wen, L. C. Pagliaro, N. M. Tannir, et al.
Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases
Clin. Cancer Res., October 1, 2007; 13(19): 5816 - 5824.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. A. Scappaticci, J. R. Skillings, S. N. Holden, H.-P. Gerber, K. Miller, F. Kabbinavar, E. Bergsland, J. Ngai, E. Holmgren, J. Wang, et al.
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
J Natl Cancer Inst, August 15, 2007; 99(16): 1232 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sandler
Bevacizumab in Non Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4613s - 4616s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Martin and R. Schilder
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Reidy, K. Y. Chung, J. P. Timoney, V. J. Park, E. Hollywood, N. T. Sklarin, R. J. Muller, and L. B. Saltz
Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes
J. Clin. Oncol., July 1, 2007; 25(19): 2691 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Meyerhardt, K Stuart, C. Fuchs, A. Zhu, C. Earle, P Bhargava, L Blaszkowsky, P Enzinger, R. Mayer, S Battu, et al.
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
Ann. Onc., July 1, 2007; 18(7): 1185 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Heiduschka, H. Fietz, S. Hofmeister, S. Schultheiss, A. F. Mack, S. Peters, F. Ziemssen, B. Niggemann, S. Julien, K. U. Bartz-Schmidt, et al.
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2814 - 2823.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J.-L. Canon, J.-L. Van Laethem, J. Maurel, G. Richardson, et al.
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
J. Clin. Oncol., May 1, 2007; 25(13): 1658 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O'Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz, and A. B. Benson III
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
J. Clin. Oncol., April 20, 2007; 25(12): 1539 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Los, J. M. L. Roodhart, and E. E. Voest
Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer
Oncologist, April 1, 2007; 12(4): 443 - 450.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. S. Panageas, L. Ben-Porat, M. N. Dickler, P. B. Chapman, and D. Schrag
When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
J Natl Cancer Inst, March 21, 2007; 99(6): 428 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Oncologist, January 1, 2007; 12(1): 38 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. S. Heier, D. S. Boyer, T. A. Ciulla, P. J. Ferrone, J. M. Jumper, R. C. Gentile, D. Kotlovker, C. Y. Chung, R. Y. Kim, and for the FOCUS Study Group
Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.
Arch Ophthalmol, November 1, 2006; 124(11): 1532 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Heidemann, D G Binion, W Domschke, and T Kucharzik
Antiangiogenic therapy in human gastrointestinal malignancies.
Gut, October 1, 2006; 55(10): 1497 - 1511.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
B. D. Zeitlin, E. Joo, Z. Dong, K. Warner, G. Wang, Z. Nikolovska-Coleska, S. Wang, and J. E. Nor
Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2.
Cancer Res., September 1, 2006; 66(17): 8698 - 8706.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Giantonio, D. Levy, P. O'Dwyer, N. Meropol, P. Catalano, and A. Benson III
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200
Ann. Onc., September 1, 2006; 17(9): 1399 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker
Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma
J. Clin. Oncol., August 20, 2006; 24(24): 4011 - 4019.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem
Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges
J. Clin. Oncol., July 20, 2006; 24(21): 3325 - 3327.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Bevacizumab and {blacktriangledown}cetuximab for colorectal cancer
DTB, May 1, 2006; 44(5): 37 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
D. Vallbohmer, J. H. Peters, H. Kuramochi, D. Oh, D. Yang, D. Shimizu, S. R. DeMeester, J. A. Hagen, P. T. Chandrasoma, K. D. Danenberg, et al.
Molecular Determinants in Targeted Therapy for Esophageal Adenocarcinoma
Arch Surg, May 1, 2006; 141(5): 476 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. R. Adams
Evolving role of antineoplastic agents in colorectal cancer
Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S4 - S11.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Townsley, G. R. Pond, A. M. Oza, H. W. Hirte, E. Winquist, G. Goss, P. Degendorfer, M. J. Moore, and L. L. Siu
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
Clin. Cancer Res., April 1, 2006; 12(7): 2141 - 2149.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Glusker, L. Recht, B. Lane, C. Ozcan, S. J. Wong, P. Hari, and H. Barron
Reversible posterior leukoencephalopathy syndrome and bevacizumab.
N. Engl. J. Med., March 2, 2006; 354(9): 980 - 982.
[Full Text] [PDF]

Home page
 JCOHome page
J. R. Goffin and J. R. Talavera
Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer
J. Clin. Oncol., January 20, 2006; 24(3): 528 - 529.
[Full Text] [PDF]

Home page
 JCOHome page
F. F. Kabbinavar, J. Hambleton, R. D. Mass, and S. Sarkar
In Reply:
J. Clin. Oncol., January 20, 2006; 24(3): 529 - 530.
[Full Text] [PDF]

Home page
 JCOHome page
A. J. Bilchik, G. Poston, S. A. Curley, S. Strasberg, L. Saltz, R. Adam, B. Nordlinger, P. Rougier, and L. S. Rosen
Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note
J. Clin. Oncol., December 20, 2005; 23(36): 9073 - 9078.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online